Resources to Help You Treat COPD

COPD Foundation Resources

The COPD Foundation was established to undertake initiatives that result in expanded services for COPD and to improve the lives of individuals affected by COPD. Get additional COPD and patient resources.

Visit COPD Foundation

COPD Assessment TestTM

The COPD Assessment Test (CAT) can help you and your patients track changes in their breathing and overall health. Use this free online resource to get your COPD patients’ CAT scores. You can print out the quiz or take it online together with patients.

See CAT Quiz

COPD Webinars & Presentations

Watch educational videos on COPD and DUAKLIR PRESSAIR, as well as access medical presentations and more resources.

Watch Now

COPD Webinar

FPO COPD video with Dr. Sanjay Sethi on Duaklir and COPD Management.

Watch now

Get the Latest on DUAKLIR. Contact Us Today!

Use this form to contact a Representative or Medical Science Liaison (MSL) and/or get updates about DUAKLIR, including new webinar videos and patient resources.

COPD Facts and Statistics

The prevalence of COPD in the US is increasing.14 Chronic lower respiratory diseases, which include COPD, are the 3rd leading cause of disease-related death in the US.15 Approximately 15 million adult Americans have been diagnosed with COPD, and it is estimated that an additional 12 million remain undiagnosed.16 

COPD typically occurs in people age 40 and above, with prevalence generally increasing with age.14,17,18

19 US States with the Highest Prevalence of COPD*:

Map of COPD Prevalence in US

*Based on the 2014 CDC Behavioral Risk Factor Surveillance System (BRFSS). Prevalence age-adjusted to the 2000 US standard population aged ≥18 years. Highlighted states have a COPD prevalence of ≥6.5%.

At-Risk Groups for COPD

COPD is the
3rd LEADING CAUSE OF DEATH in the United States due to Disease19

15 MILLION

Americans have been diagnosed with COPD

12 MILLION

Americans remain undiagnosed

The prevalence of COPD is HIGHER in WOMEN than in MEN, especially for cigarette smokers14,18

Primary Cause20,21

~85-90% of COPD cases caused by smoking

Other risk factors include:

Indoor air pollution

Outdoor air pollution

Occupational dust and chemicals

Secondhand smoke

Indication and Usage

DUAKLIR PRESSAIR (aclidinium bromide/formoterol fumarate inhalation powder) is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Important Safety Information

  • DUAKLIR PRESSAIR (aclidinium bromide/formoterol fumarate inhalation powder) is only indicated for use in COPD and is not indicated for use in asthma. Use of a long-acting beta2-adrenergic agonist (LABA) as monotherapy, including formoterol fumarate, one of the active ingredients in DUAKLIR PRESSAIR, without an inhaled corticosteroid (ICS) is contraindicated in patients with asthma and increases the risk of asthma-related death. When LABA are used in fixed-dose combinations with ICS, data from large clinical trials do not show a significant increase in the risk of serious asthma-related events (hospitalizations, intubations, death) compared to ICS alone.
  • DUAKLIR PRESSAIR is contraindicated in patients with severe hypersensitivity to milk proteins or who have hypersensitivity to aclidinium bromide or formoterol fumarate or any component of the product
  • DUAKLIR PRESSAIR is not indicated for the treatment of acute episodes of bronchospasm (i.e. rescue therapy)
  • Do not initiate DUAKLIR PRESSAIR with an additional medicine containing a LABA because of risk of overdose or in acutely deteriorating COPD
  • Immediate hypersensitivity reactions, including anaphylaxis, angioedema (swelling of lips, tongue, or throat), urticaria, rash, bronchospasm, or itching have occurred after administration of DUAKLIR PRESSAIR. Additionally, inhaled medicines, including DUAKLIR PRESSAIR, may cause paradoxical bronchospasm which may be life threatening. If any of these occurs, immediate treatment with a short acting bronchodilator should be initiated and treatment with DUAKLIR PRESSAIR should be stopped and alternative therapy initiated
  • DUAKLIR PRESSAIR should be used with caution in patients with cardiovascular and convulsive disorders, thyrotoxicosis, diabetes mellitus, ketoacidosis, hypokalemia, hyperglycemia, narrow-angle glaucoma or urinary retention. Instruct patients to consult a physician immediately should any signs or symptoms of acute narrow-angle glaucoma or prostatic hyperplasia or bladder-neck obstruction develop
  • The most common adverse reactions (≥3% incidence and more common than placebo) were upper respiratory tract infection (8.9% vs 6.3%), headache (6.3% vs 5.1%), and back pain (3.8% vs 3.4%) for DUAKLIR PRESSAIR vs placebo, respectively. Other adverse reactions reported in clinical studies (>1% but less than 3% and more common than placebo) with DUAKLIR PRESSAIR were cough, sinusitis, influenza, tooth abscess, insomnia, dizziness, dry mouth, oropharyngeal pain, muscle spasm, musculoskeletal pain, arthralgia, pain in extremity, urinary tract infection, and increased blood creatine phosphokinase

Medical Information

For answers to your medical questions about DUAKLIR PRESSAIR, please contact Circassia Medical Information at medinfo.us@circassia.com.

Please also see the full Prescribing Information, including Patient Information.

MORE IMPORTANT SAFETY INFORMATION

  • DUAKLIR PRESSAIR (aclidinium bromide/formoterol fumarate inhalation powder) is only indicated for use in COPD and is not indicated for use in asthma. Use of a long-acting beta2-adrenergic agonist (LABA) as monotherapy, including formoterol fumarate,
  • DUAKLIR PRESSAIR (aclidinium bromide/formoterol fumarate inhalation powder) is only indicated for use in COPD and is not indicated for use in asthma. Use of a long-acting beta2-adrenergic agonist (LABA) as

Indication and Usage

DUAKLIR PRESSAIR (aclidinium bromide/formoterol fumarate inhalation powder) is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Important Safety Information

  • DUAKLIR PRESSAIR (aclidinium bromide/formoterol fumarate inhalation powder) is only indicated for use in COPD and is not indicated for use in asthma. Use of a long-acting beta2-adrenergic agonist (LABA) as monotherapy, including formoterol fumarate, one of the active ingredients in DUAKLIR PRESSAIR, without an inhaled corticosteroid (ICS) is contraindicated in patients with asthma and increases the risk of asthma-related death. When LABA are used in fixed-dose combinations with ICS, data from large clinical trials do not show a significant increase in the risk of serious asthma-related events (hospitalizations, intubations, death) compared to ICS alone.
  • DUAKLIR PRESSAIR is contraindicated in patients with severe hypersensitivity to milk proteins or who have hypersensitivity to aclidinium bromide or formoterol fumarate or any component of the product
  • DUAKLIR PRESSAIR is not indicated for the treatment of acute episodes of bronchospasm (i.e. rescue therapy)
  • Do not initiate DUAKLIR PRESSAIR with an additional medicine containing a LABA because of risk of overdose or in acutely deteriorating COPD
  • Immediate hypersensitivity reactions, including anaphylaxis, angioedema (swelling of lips, tongue, or throat), urticaria, rash, bronchospasm, or itching have occurred after administration of DUAKLIR PRESSAIR. Additionally, inhaled medicines, including DUAKLIR PRESSAIR, may cause paradoxical bronchospasm which may be life threatening. If any of these occurs, immediate treatment with a short acting bronchodilator should be initiated and treatment with DUAKLIR PRESSAIR should be stopped and alternative therapy initiated
  • DUAKLIR PRESSAIR should be used with caution in patients with cardiovascular and convulsive disorders, thyrotoxicosis, diabetes mellitus, ketoacidosis, hypokalemia, hyperglycemia, narrow-angle glaucoma or urinary retention. Instruct patients to consult a physician immediately should any signs or symptoms of acute narrow-angle glaucoma or prostatic hyperplasia or bladder-neck obstruction develop
  • The most common adverse reactions (≥3% incidence and more common than placebo) were upper respiratory tract infection (8.9% vs 6.3%), headache (6.3% vs 5.1%), and back pain (3.8% vs 3.4%) for DUAKLIR PRESSAIR vs placebo, respectively. Other adverse reactions reported in clinical studies (>1% but less than 3% and more common than placebo) with DUAKLIR PRESSAIR were cough, sinusitis, influenza, tooth abscess, insomnia, dizziness, dry mouth, oropharyngeal pain, muscle spasm, musculoskeletal pain, arthralgia, pain in extremity, urinary tract infection, and increased blood creatine phosphokinase

Medical Information

For answers to your medical questions about DUAKLIR PRESSAIR, please contact Circassia Medical Information at medinfo.us@circassia.com.

Please also see the full Prescribing Information, including Patient Information.

REFERENCES: 1. Loveridge B, et al. Am Rev Respir Dis. 1986;134(5):930-934. 2. Duaklir® Pressair® (aclidinium bromide/formoterol fumarate inhalation powder)[prescribing information]. Morrisville, NC: Circassia Pharmaceuticals Inc; 2019. 3. Sethi S, et al. International Journal of COPD. 2019;14:667-682. 4. Data on file, Circassia. 5. Jones PW, et al. Respir Med. 1991;85(suppl B):25-31. 6. D'Urzo AD, et al. Respir Res. 2014;15:123. 7. Miravitlles M, et al. Respir Res. 2014;15:122. 8. Balachandran J, et al. Am J Respir Grit Care Med. 2013;188:5-6. 9. Singh D, et al. BMC Pulmonary Medicine. 10. Cote CG, et al. Chest. 2008;134:104001. 11. Wise RA, et al. JAMA. 2019;321(17):1693-1701. 12. Tudorza® Pressair® (aclidinium bromide inhalation powder) [prescribing information]. Morrisville, NC: Circassia Pharmaceuticals Inc; 2019. 13. Ocakli B, et al. Int J Chron Obstruct Pulmon Dis. 2018;13:2941-2947. 14. Centers for Disease Control and Prevention. Chronic Obstructive Pulmonary Disease Among Adults – United States, 2011. MMWR. Nov 2012;61(46);938-943. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6146a2.htm?s_cid=mm6146a2_w. Accessed April 7, 2016. 15. Centers for Disease Control and Prevention. Deaths: Leading Causes for 2017. National Vital Statistics Reports. 2019;68(6). https://www.cdc.gov/nchs/data/nvsr/nvsr68/nvsr68_06-508.pdf. Published June 24, 2019. Accessed August 19, 2019. 16. National Heart, Lung, and Blood Institute (NHLBI). Morbidity & Mortality: 2012 Chart Book on Cardiovascular, Lung, and Blood Diseases. http://www.nhlbi.nih.gov/files/docs/research/2012_ChartBook_508.pdf. Published February 2012. Accessed April 7, 2016. 17. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. https://goldcopd.org/wp-content/uploads/2018/11/GOLD-2019-v1.7-FINAL-14Nov2018-WMS.pdf. Updated November 2018. Accessed July 16, 2019. 18. Ford ES, Croft JB, Mannino DM, Wheaton AG, Zhang X, Giles WH. COPD Surveillance–United States, 1999-2011. Chest. 2013;144(1):284-305. 19. Chronic Obstructive Pulmonary Disease (COPD) Includes: Chronic Bronchitis and Emphysema. National Center for Health Statistics website. https://www.cdc.gov/nchs/fastats/copd.htm. Updated May 3, 2017. Accessed July 16, 2019. 20. American Lung Association. What Causes COPD. http://www.lung.org/lung-health-and-diseases/lung-disease-lookup/copd/symptoms-causes-risk-factors/what-causes-copd.html. Published 2016. Accessed April 7, 2016. 21. World Health Organization. Causes of COPD. http://www.who.int/respiratory/copd/causes/en/#. Accessed April 7, 2016.

Close

TERMS OF USE

Eligible commercially insured patients with a valid prescription for Duaklir® Pressair® (aclidinium bromide/formoterol fumarate) who present this savings card at participating pharmacies will pay $10 per 30-day supply (1 inhaler) if their out-of-pocket cost is more than $10. For eligible patients without insurance please call the Circassia Connect Hotline at 1-844-892-7872. This offer is good for 12 uses and each inhaler counts as 1 use. Other restrictions may apply. Patient is responsible for applicable taxes, if any. Card expires on 12/31/2020. If patient has any questions regarding this offer, please call 1-844-892-7872.

Non-transferable, limited to one per person, cannot be combined with any other offer. Void where prohibited by law, taxed or restricted. Patients, pharmacists, and prescribers cannot seek reimbursement from health insurance or any third party for any part of the benefit received by the patient through this offer.

Circassia reserves the right to rescind, revoke, or amend this offer, eligibility and terms of use at any time without notice. This offer is not conditioned on any past, present or future purchase, including refills. Offer must be presented along with a valid prescription for DUAKLIR PRESSAIR at the time of purchase.

If a patient’s commercial insurance plan does not cover DUAKLIR PRESSAIR, use of this offer permits his/her healthcare provider or pharmacy to share limited information with certain Circassia vendors to determine if additional resources may be available, and to act on his/her behalf to initiate any processes that may be necessary to access these resources.

BY USING THIS CARD, YOU AND YOUR PHARMACIST UNDERSTAND AND AGREE TO COMPLY WITH THESE ELIGIBILITY REQUIREMENTS AND TERMS OF USE.

Pharmacist Instructions for a Patient With an Eligible Third-Party Payer: For Insured/Covered Patients: Submit the claim to the primary Third-Party Payer first, then submit the balance due to Change Healthcare as a Secondary Payer COB with patient responsibility amount and a valid Other Coverage Code of 8. This will reduce the eligible patient’s out-of-pocket costs to $10 on a 30-day supply.

Eligibility

You may be eligible for this offer if you are insured by commercial insurance and your insurance does not cover the full cost of your prescription or denies coverage of DUAKLIR PRESSAIR completely.

Patients who are enrolled in a state or federally funded prescription insurance program are not eligible for this offer. This includes patients enrolled in Medicare Part D, Medicaid, Medigap, Veterans Affairs (VA), Department of Defense (DOD) programs or TriCare, and patients who are Medicare eligible and enrolled in an employer-sponsored group waiver health plan or government-subsidized prescription drug benefit program for retirees.

If you are enrolled in a state or federally funded prescription insurance program, you may not use this savings card even if you elect to be processed as an uninsured patient.

This offer is not insurance, is restricted to residents of the United States and to patients over 18 years of age. If you use a mail-order pharmacy, please contact your pharmacy provider to confirm if this offer will be accepted.